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Abstract
This review provides an introduction to mass spectrometry based proteomics and discusses several proteomics
approaches that are relevant in understanding the pathophysiology of fibrotic disorders and the approaches that
are frequently used in biomarker discovery.
Introduction
What are the changes in protein levels that occur during
or because of fibrosis? What are the signaling mechan-
isms associated with fibrosis? Mass spectrometry based
proteomics has been successfully used to study many
diseases in order to identify potential biomarkers and/or
understand pathogenesis, however, there haven’tb e e n
many studies devoted to understanding proteins and
their post-translational modifications (PTM) as con-
nected with fibrosis in different tissues.
One of the reasons for this is probably technological -
up to recent years the majority of proteomics techniques
were not sensitive enough to identify and/or quantify
minor changes in protein expression levels. The analysis
of PTMs, on the other hand, is challenging because those
modifications are usually in low abundance, complex or
transient in nature. This overview will discuss mass spec-
trometry based proteomics techniques for protein char-
acterization and point out those studies that have
successfully used the approaches to study fibrosis and to
search for potential biomarkers in fibrotic tissues or
patients plasma.
Discussion
Proteomics strives to characterize proteins and their role
in complex biological systems. It is only one of the compo-
nents of -omics approaches which - when fully applied to
a biological problem - will generate a composite picture of
biological processes. Mass spectrometry based proteomics
is the first step to study the changes that proteins undergo
as a consequence of fibrotic disorder, whether the changes
are in protein levels (e.g. differential protein expression),
temporal (following the development of a disorder), or on
the post-translational level (e.g. phosphorylation) as com-
pared to the control, healthy tissue or plasma. The final
goal of many proteomics studies is the discovery of a bio-
marker protein or a protein panel that enables detection
of disease, can monitor and measure the treatment pro-
gress and could also predict development of the disease.
Majority of studies so far have used patient plasma to elu-
cidate the mechanisms of fibrosis or find its putative bio-
m a r k e r sa sc o m p a r e dt or e l a t i v e l yf e ws t u d i e st h a tu s e
either tissues after biopsy or animal models/cell lines.
Mass spectrometry based proteomics
Mass spectrometry is routinely used to identify proteins,
quantify their levels (relative or absolute) and to character-
ize protein post-translational modifications. Some useful
reviews on the application of different mass spectrometry
based approaches were written by Yates et al. [1,2] and
Cox et al. [3].
The advancements in the mass spectrometric technol-
ogy, such as in instrument designs (dual pressure ion
trap) and mass analyzers (orbitrap) have significantly
improved the sensitivity and mass accuracy. Nevertheless,
sample preparation and fractionation are very important
especially when dealing with scarce clinical samples to be
able to characterize high numbers of proteins and their
post-translational modifications. Dealing with tissue sam-
ples or plasma poses additional challenges because of
sample stability, solubility and abundance issues. Proteins
in tissues are usually difficult to solubilize (which is criti-
cal for a successful tryptic digestion), whereas plasma
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mask and thus prevent the identification of lower abun-
dant proteins (such as signaling molecules and putative
biomarkers). With the depletion of most abundant
plasma proteins (up to 20), this approach then enables
mass-spectrometry based proteomics to dig deeper into
plasma proteome in order to identify low abundant pro-
teins and their possible modifications.
The final goal of many proteomics experiments is to
completely characterize a proteome: protein’si d e n t i f i c a -
tion, location, function, interacting partners, post-transla-
tional modifications (PTMs) and in many cases also the
turnover rate of protein production/degradation or the rate
of formation for a particular PTM. We would also like to
know what are the occupancies for a particular PTM (e.g.
what percentage of a given site in protein is phosphory-
lated). Some recent reviews on PTMs are the following:
phosphorylation [4-6], acetylation [7], S-nitrosylation [8],
glycosylation [9], ubiquitination [10], etc.
Relative protein quantitation as a tool in biomarker
discovery
Mass spectrometry is an indispensible tool for relative pro-
tein quantitation which is usually applied to discovery of
clinical biomarkers and mostly uses large-scale proteomics
experiments. The first step in a typical large scale proteo-
mics experiment is a separation technique on either the
protein (e.g. 1D gel) or peptide level (e.g. SCX - strong
cation exchange chromatography), followed by analysis of
each of the individual fractions with liquid chromatogra-
phy coupled to tandem mass spectrometry system (LC-
MS/MS). The liquid chromatography is mostly reverse
phase based with the flows in nanoliter range. Usually, 1D
gel separation on protein level followed by an LC-MS/MS
analysis gives a higher number of identified proteins
because the first dimension separation is on the protein
level as compared to SCX which separates peptides on the
basis of charge. A summary of proteomics approaches
using mass spectrometry is depicted in Figure 1.
The analysis of PTMs usually involves enrichment
which is based on an antibody pull-down or it takes
advantage of some physicochemical property of the PTM
to selectively target proteins or peptides with that PTM.
For example, tyrosine (Tyr) phosphorylated proteins (or
peptides) are easily enriched by using a specific anti-pTyr
antibody. On the other hand, serine or threonine phos-
phorylated proteins or peptides are enriched by using
immobilized-metal affinity chromatography (IMAC) and
metal-oxide affinity chromatography (e.g. TiO2 based).
After the enrichment, the mass spectrometric analysis
can pose some difficulties as well. A lot of PTMs are
labile modifications that can easily fragment under colli-
sionally induced dissociation in mass spectrometer [4].
There are several complementary approaches for rela-
tive protein quantification, such as DIGE (2D floures-
cence difference gel electrophoresis) [11], iTRAQ
(isobaric tag for relative and absolute quantitation) [12]
and SILAC (stable isotope labeling with amino acids in
cell culture) [13], with DIGE being used the most in stu-
dies of fibrotic disorders.
Two-dimensional gels are an excellent way to separate
proteins on the basis of their molecular weight and iso-
electric point, enabling also visualization of some post-
translational modifications (such as phosphorylation). In
the quantitative approach (DIGE), two protein samples
are labeled with fluorescent dyes and when combined
and separated on a 2D gel can be visualized by measuring
the fluorescence showing whether a protein is up- or
Figure 1 Mass spectrometry based proteomics relies on the separation of proteins using gels or chromatography, digestion with an
enzyme and further analysis by mass spectrometry. Bioinformatics tools help in identification and quantification of proteins.
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individual spots of interest is carried out by mass spectro-
metry. The gels are usually scaled up (pick gel), stained
with Coomassie blue, excised and digested with trypsin
before being analyzed on a MALDI TOF/TOF or electro-
s p r a yt y p eo fa ni n s t r u m e n t .S i n c ef l u o r e s c e n c ec a nb e
very sensitive, it is sometimes difficult to identify the pro-
teins in spots by mass spectrometry which is a couple of
orders less sensitive. Another drawback of this approach
is that sometimes the individual spots may provide
several identifications with similar proteins co-eluting.
As a complementary technique to DIGE, iTRAQ has
recently gained a lot of popularity in the protein bio-
marker applications because of the ability to multiplex
several samples in one run (up to 8) and because the
number of identified proteins are usually higher.
Proteomic analysis of fibrotic samples
Proteomic analysis of fibrotic tissue is further complicated
with the limited ability of most common techniques to
solubilize proteins in a complicated matrix. Usually, the
number of identified proteins from a tissue sample is
smaller as compared to a cell lysate. Most of the biologi-
cally important proteins (such as proteins involved in sig-
naling mechanisms) are of lower abundance, thus it is
essential to identify as many proteins as possible. The
other drawback associated with fibrotic tissue analysis is
limitation with the quantitation techniques because some
of them due to the nature of labeling cannot be applied
( e . g .S I L A Cv s .i T R A Q ) .P l a s m as a m p l e s ,o nt h eo t h e r
hand, pose challenges as well, mainly due to high abun-
dant proteins that are usually depleted to enable identifica-
tion of less abundant proteins in the sample.
Proteomics studies on organ fibrosis
Liver
Liver fibrosis has been relatively well studied using available
proteomics tools and there are detailed reviews that criti-
cally discuss the use of proteomic approaches in hepatic
fibrosis, including the search for putative biomarkers
[14,15]. In a recent study, Lu et al. [16] carried out an
extensive study using plasma samples from patients with
and without chronic hepatitis B virus (HBV) infection.
They used DIGE approach on pooled samples and identi-
fied potential biomarkers which were followed up by wes-
tern blots on individual samples. Peroxiredoxin 2 is
upregulated in fibrotic patients and could be potentially
used in early diagnosis of HBV related liver fibrosis. Similar
DIGE approaches were successfully used to study changes
in the hepatic proteome after treatment with a traditional
Chinese herbal medicine [17] and to discover novel biomar-
ker candidate for liver cirrhosis [18-21]. Some of the
approaches used tissue as starting material and others
plasma with or without depletion of most abundant
proteins.
Kidney
Renal fibrosis and complex proteomics associated with
chronic kidney disease has been reviewed in a recent
paper by Klein et al. [22]. Two other useful reviews focus
on plasma and urine biomarkers of kidney disease
[23,24]. A lot of discussion is devoted into pros and cons
of using animal models (or even cell lines) to assess the
markers for renal fibrosis. In a recent study, Dihazi et al.
used a cell model with renal fibrosis phenotype coupled
with DIGE to identify 30 regulated proteins in fibrotic
compared to normal kidney fibroblasts [25].
Lungs
Idiopathic pulmonary fibrosis (IPF) - which is a disease of
unknown etiology and is connected to progressive lung
fibrosis - is the most studied condition related to lung
fibroproliferative disorders. Kinulla et al. [26] reviewed the
proteomics approaches applied to two different disease
types: chronic obstructive pulmonary disease and idio-
pathic pulmonary fibrosis, pointing out that a lot of times
proteomics studies compile the protein lists but fail to
describe and elucidate the mechanisms behind these
changes on the protein or PTM levels. Other useful
reviews on lung-related fibrotic diseases and potential bio-
markers were written by Lau et al. [27], Levine [28] and
Govender et al. [29].
Among interesting proteins revealed and further studied
by proteomics approaches, apolipoprotein A-I may be use-
ful in therapeutic strategies after it was recently shown
that its levels are decreased in IPT lungs compared to nor-
mal tissue animal models [30]. Similarly, another study
revealed reduced levels of the receptor for advanced glyca-
tion end products (RAGE) protein which is a key player in
cellular signaling [31].
Systemic sclerosis
Castro et al. [32] critically discussed biomarkers in sys-
temic sclerosis, pointing out that the proteomics studies
dealing with systemic sclerosis have mostly focused on
pathophysiology rather than trying to find biomarkers
connected with onset, progression and treatment of this
condition. Another review by Abignano et al. [33] focuses
on comprehensive -omics approaches to identify possible
scleroderma biomarkers.
Scambi et al. [34] investigated sera from patients with
scleroderma and patients with sclerodermatous graft-
versus-host disease using DIGE proteomics approach to
reveal 14 differentially expressed proteins, including fac-
tor H which could affect its binding to endothelial cells.
Conclusions
Mass spectrometry based proteomics is a powerful tool to
identify proteins and their posttranslational modifications.
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sample preparation is critical - with biological fluids it is
possible to remove the most abundant proteins by immu-
nodepletion. Liver fibrosis has been relatively well studied
using available proteomics tools and there are several pos-
sible biomarkers that were identified by using proteomics
approaches.
The current state of technology definitely brings along a
lot of opportunities, and challenges as well, especially with
the data analysis and making sense of the protein lists.
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